AffiliationDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK.
MetadataShow full item record
AbstractTemozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combination chemotherapy. Trials to date have focussed on its activity in advanced metastatic melanoma and high-grade malignant glioma. Investigations into other indications, in particular solid tumors with central nervous system metastases, are ongoing. Studies of new drug schedules and of drugs to ameliorate temozolomide resistance offer the prospect of increased efficacy.
CitationTemozolomide: a novel oral alkylating agent. 2001, 1 (1):13-9 Expert Rev Anticancer Ther
JournalExpert Review of Anticancer Therapy
- Temozolomide and treatment of malignant glioma.
- Authors: Friedman HS, Kerby T, Calvert H
- Issue date: 2000 Jul
- Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
- Authors: Agarwala SS, Kirkwood JM
- Issue date: 2000
- New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
- Authors: Spiro T, Liu L, Gerson S
- Issue date: 2000 Jul-Sep
- New approaches for temozolomide therapy: use in newly diagnosed glioma.
- Authors: Stupp R, Newlands E
- Issue date: 2001 Aug
- Temozolomide for Treating Malignant Melanoma.
- Authors: Li RH, Hou XY, Yang CS, Liu WL, Tang JQ, Liu YQ, Jiang G
- Issue date: 2015 Sep